Multi-country oncology trial share vs Oncology novel active substance (NAS) launches (cumulative)
In 2015, multi-country oncology trial share worldwide was 37%; oncology novel active substance (NAS) launches (cumulative) was 79.
Change the pair
Compare different indicators
The series
Over time
Global, spaced by time in 2015 . Different units, drawn on separate scales and clipped to the years both series publish — earlier history stays on each indicator's own page. Read the values, not the heights.
Multi-country oncology trial share
Unit: % · 1 observation
View the underlying data
| Period | Type | Value |
|---|---|---|
| 2015 | Actual | 37% |
Oncology novel active substance (NAS) launches (cumulative)
Unit: count · 1 observation
View the underlying data
| Period | Type | Value |
|---|---|---|
| 2015–2019 | Actual | 79 |
Shared periods
Side by side
Only one period is published for both series. Comparing anything else would mean comparing different years.
Provenance
Where these numbers come from
Multi-country oncology trial share
Share of oncology trial starts that were multi-country studies.
2 observations in Global · source organisations: IQVIA
Oncology novel active substance (NAS) launches (cumulative)
Total number of oncology novel active substances launched over a stated multi-year period.
3 observations in Global · source organisations: IQVIA
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring